BK nephropathy: what is the role of antiviral therapy?
Fishman
Jay A
JA
D000998:Antiviral Agents / Q000627:therapeutic use*; D001739:BK Virus / Q000502:physiology; D000077404:Cidofovir; D003596:Cytosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006084:Graft Rejection / Q000276:immunology / Q000821:virology; D006801:Humans; D016867:Immunocompromised Host / Q000276:immunology; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000276:immunology; D009393:Nephritis / Q000188:drug therapy* / Q000821:virology*; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000627:therapeutic use; D027601:Polyomavirus Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000821:virology; D016896:Treatment Outcome; D014412:Tumor Virus Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000821:virology; D019562:Viral Load; D014779:Virus Replication
D000998:Antiviral Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D003596:Cytosine; D000077404:Cidofovir